Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

220.90 -3.61 (-1.61%)
Streaming Delayed Price Updated: 1:52 PM EDT, Sep 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 191,717
Open 221.15
Bid (Size) 220.58 (200)
Ask (Size) 221.16 (100)
Prev. Close 224.51
Today's Range 219.82 - 223.82
52wk Range 135.39 - 225.80
Shares Outstanding 146,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Biogen Inc.
Via GlobeNewswire
News headline image
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Stoke Therapeutics, Inc.
Via Business Wire

Performance

YTD
+24.2%
+24.2%
1 Month
+6.0%
+6.0%
3 Month
+12.4%
+12.4%
6 Month
+17.5%
+17.5%
1 Year
+56.0%
+56.0%

More News

Read More
News headline image
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Stoke Therapeutics, Inc.
Via Business Wire
Biogen (NASDAQ:BIIB) Shows Strong Technical Breakout Setup With Perfect Trend Rating ↗
Via Chartmill
These S&P500 stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Biogen Inc.
Via GlobeNewswire
News headline image
Q2 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
Unpacking Q2 Earnings: Novavax (NASDAQ:NVAX) In The Context Of Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons to Sell BIIB and 1 Stock to Buy Instead
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
Therapeutics Stocks Q2 Results: Benchmarking BioMarin Pharmaceutical (NASDAQ:BMRN)
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen (BIIB) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Biogen Completes Acquisition of RayThera Inc.
From Biogen Inc.
Via GlobeNewswire
News headline image
The 5 Most Interesting Analyst Questions From Biogen’s Q2 Earnings Call
Via StockStory
Topics Earnings
News headline image
Why Supernus Pharmaceuticals Stock Topped the Market Today ↗
Via The Motley Fool
News headline image
BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook
Via StockStory
News headline image
Why Biogen Stock Topped the Market Today ↗
Via The Motley Fool
News headline image
Biogen Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026
Via StockStory
News headline image
Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings
Via StockStory
Topics Artificial Intelligence
News headline image
3 Profitable Stocks We Steer Clear Of
Via StockStory
News headline image
Biogen Appoints Michael J. Parini as Chief Legal Officer
From Biogen Inc.
Via GlobeNewswire
News headline image
3 Reasons to Avoid BIIB and 1 Stock to Buy Instead
Via StockStory
Topics Stocks
Discover which S&P500 stocks are making waves on Tuesday. ↗
Via Chartmill
News headline image
Biogen Backs Alzheimer’s Tau Drug for Phase 3 Despite Trial Miss ↗
Via MarketBeat
These S&P500 stocks are moving in today's session ↗
Via Chartmill

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 220.90
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 09/04/26 01:52 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 32.43B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 32B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.